The Treatment and Prognosis of Primary Hepatobiliary Cancer: A Cohort Study in Central China
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This registry is designed as a longitudinal cohort study of patients diagnosed with primary hepatobiliary cancer in Tongji Hospital, Wuhan. This study collects the clinical-pathological features of hepatic malignant tumors and the current status of patients who received comprehensive treatment based on surgical treatment since 1998.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥18 years old,
• life expectancy is at least 6 months.
• Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or confirmed by imaging as HCC (by the AASLD or guidance for the diagnosis and treatment of primary liver cancer of China (version 2022).
• At least one measurable lesion (RECIST v1.1)
• Subjects volunteer to participate in the study and sign informed consent.
Locations
Other Locations
China
Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Bixiang Zhang, PhD
bixiangzhang@hust.edu.cn
86-027-83665293
Time Frame
Start Date: 2020-05-01
Estimated Completion Date: 2025-03-31
Participants
Target number of participants: 2000
Related Therapeutic Areas
Sponsors
Collaborators: Gelesis, Inc., Geneplus-Beijing Co. Ltd., YuceBio Technology, Chinese Cooperative Group of Liver Cancer, Haplox Biotechnology Co., Ltd., Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
Leads: Tongji Hospital